ZAGREB, Nov 28 (Hina) - Croatian pharmaceutical company Pliva held a day of research and development in London Wednesday, in order to inform investors and analysts about the status and development of its pipeline (activities in the
area of development), Zeljko Covic, chairman of Pliva's Management Board said Wednesday. At the moment, Pliva has more than 50 generic products under development of which more than 20 are expecting submissions for international registration by the end of 2001, Covic said. We are aiming at launching ten to 15 new generic products each year developed by us, and we are predicting that our newly developed generics will be sold on markets of Central and East Europe in 2005 for amounts exceeding USD90 million, Covic said. Pliva's balanced and dual strategy, dedicated to both generic and proprietary drugs, is yielding results, creating a solid ground fo
ZAGREB, Nov 28 (Hina) - Croatian pharmaceutical company Pliva held
a day of research and development in London Wednesday, in order to
inform investors and analysts about the status and development of
its pipeline (activities in the area of development), Zeljko Covic,
chairman of Pliva's Management Board said Wednesday.
At the moment, Pliva has more than 50 generic products under
development of which more than 20 are expecting submissions for
international registration by the end of 2001, Covic said.
We are aiming at launching ten to 15 new generic products each year
developed by us, and we are predicting that our newly developed
generics will be sold on markets of Central and East Europe in 2005
for amounts exceeding USD90 million, Covic said.
Pliva's balanced and dual strategy, dedicated to both generic and
proprietary drugs, is yielding results, creating a solid ground for
the company?s growth in short and long runs, Covic said. He added
that investing in research and development, which are accountable
for about nine percent of the company's revenue, should result in
sustainable revenue growth and an increase in the value of Pliva's
shares.
Pliva has a long standing tradition in the area of biotechnology,
and five biopharmaceutical products in development at present,
which will assure Pliva's competition at a market whose turnover in
2000 was estimated to USD11.5 billion, and expected to reach
USD17.5 billion in 2004.
Next to a series of projects in researching stage, and pre-clinic
tests, three products are currently in the phase of clinical
development: peptide for curing inflammatory intestine illnesses,
a new substance for curing thrombocytopenia, and a new substance
for curing fungus infections.
(hina) np sb